Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab SC in RA (Latin America)
NCT02011334Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Oct 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Disease Activity Score 28-erythrocyte sedimentation rate Remission Rate at 24 weeks. Started Jul 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02011334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011334.